HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and maintained a $15 price target on the stock.
January 04, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Rigel Pharmaceuticals with a $15 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst could lead to increased investor confidence in RIGL, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100